Fig. 3. Therapeutic efficacy of GS-621763.
a Schematic of the therapeutic efficacy study design. Ferrets were infected intranasally with 1 × 105 pfu WA1/2020. Symbols as described for Fig. 2a. Starting 12 h after infection, groups of ferrets (n = 4) were gavaged b.i.d. with vehicle (black circles in b–g), GS-621763 (3 mg/kg (purple first aid symbol; purple circles in b–g) or 10 mg/kg (pink first aid symbol; red circles in b–g)), or treated with EIDD-2801 (5 mg/kg (green first aid symbol; green diamonds in b-g)). Nasal lavages were harvested twice daily. Animals were terminated 4 days after infection. b Virus titers from nasal lavages. c, Infectious titers of SARS-CoV-2 in nasal turbinates harvested four days after infection. d Temperature measurements collected once daily. e Body weight measured once daily. f SARS-CoV-2 RNA copies present in nasal lavages. g SARS-CoV-2 RNA copies detected in nasal turbinates. The number of independent biological repeats (individual animals) is shown in each subpanel. Symbols represent independent biological repeats, lines (b, d, e, f) and bar graphs (c, g) connect or show samples mean, respectively, and P values are stated. 1-way (c, g) or 2-way (b, d, e, f) ANOVA with Dunnett’s post hoc multiple comparison tests. LoD limit of detection.